[FOLD] Amicus Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.99 Change: 0.46 (10.15%)
Ext. hours: Change: 0 (0%)

chart FOLD

Refresh chart

Description: Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company?s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha g

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-40.12% ROE-74.29% ROI-61.43%
Current Ratio7.19 Quick Ratio Long Term Debt/Equity0.07 Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.06 M Cash From Investing Activities21.66 M Cash From Operating Activities-20.98 M Gross Profit
Net Profit-24.29 M Operating Profit-24.06 M Total Assets192.62 M Total Current Assets151.25 M
Total Current Liabilities21.02 M Total Debt14.4 M Total Liabilities88.61 M Total Revenue
Technical Data
High 52 week17.09 Low 52 week8.38 Last close12.25 Last change-2.62%
RSI35.01 Average true range0.62 Beta1.18 Volume3.52 M
Simple moving average 20 days-6.53% Simple moving average 50 days-8.64% Simple moving average 200 days0.24%
Performance Data
Performance Week-3.77% Performance Month-4.82% Performance Quart7.27% Performance Half13.64%
Performance Year-23.72% Performance Year-to-date27.87% Volatility daily2.42% Volatility weekly5.4%
Volatility monthly11.07% Volatility yearly38.34% Relative Volume222.44% Average Volume3.04 M
New High New Low

News

2019-06-19 21:59:00 | Is Amicus Therapeutics, Inc. FOLD A Good Stock To Buy?

2019-06-13 07:30:00 | Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership

2019-06-12 17:49:39 | New Jersey biotech firm scales back Lake Nona plans

2019-06-12 08:44:00 | 2 Small Biotechs With Sagging Shares but Promising Prospects

2019-06-07 09:30:01 | Why Is Amicus Therapeutics FOLD Down 9.6% Since Last Earnings Report?

2019-06-04 16:01:00 | Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock

2019-06-03 07:00:00 | Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences

2019-05-31 07:34:40 | The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

2019-05-30 21:00:00 | Amicus Therapeutics Prices Underwritten Offering of Common Stock

2019-05-30 16:29:00 | Why NIO, PVH, and Amicus Therapeutics Slumped Today

2019-05-30 14:11:00 | Here's Why Amicus Therapeutics Fell as Much as 15.6% Today

2019-05-30 10:34:00 | 2 Ultra-High-Growth Biotech Stocks to Buy Now

2019-05-30 07:33:27 | The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

2019-05-29 16:14:50 | Amicus Therapeutics Announces Public Offering of Common Stock

2019-05-29 11:36:45 | Amicus, Penn expand gene therapy collaboration in a big way

2019-05-29 06:30:00 | Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration

2019-05-24 09:00:02 | Here Are Amicus’s Key Research Programs in 2019

2019-05-24 07:30:29 | How Is Amicus Therapeutics’ Galafold Placed in the First Quarter?

2019-05-23 11:10:02 | Comparing the EPS Trajectory of FOLD and PTLA in Fiscal 2019

2019-05-23 09:40:02 | FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019

2019-05-23 08:08:46 | What Are Analysts Recommending for FOLD and PTLA in May?

2019-05-13 17:00:00 | Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors

2019-05-10 07:00:00 | Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

2019-05-09 15:21:07 | Amicus' FOLD Earnings & Revenues Miss Estimates in Q1

2019-05-08 18:18:09 | Edited Transcript of FOLD earnings conference call or presentation 8-May-19 12:30pm GMT

2019-05-08 16:23:41 | Amicus Therapeutics Inc FOLD Q1 2019 Earnings Call Transcript

2019-05-08 08:25:12 | Amicus Therapeutics FOLD Reports Q1 Loss, Lags Revenue Estimates

2019-05-08 07:24:22 | Amicus Therapeutics: 1Q Earnings Snapshot

2019-05-08 07:00:00 | Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates

2019-05-03 09:51:01 | What's in Store for Catalyst Pharma CPRX Q1 Earnings?

2019-05-01 10:33:02 | Analysts Estimate Amicus Therapeutics FOLD to Report a Decline in Earnings: What to Look Out for

2019-04-30 20:00:00 | 3 Growth Stocks to Buy and Hold for the Next 50 Years

2019-04-30 08:06:00 | The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

2019-04-30 06:00:00 | Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy ASGCT 22nd Annual Meeting

2019-04-25 07:00:00 | Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019

2019-04-15 15:36:34 | FOLD Stock Could See a Surge Soon, Says Signal

2019-04-15 12:00:00 | Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy ASGCT 22nd Annual Meeting

2019-04-10 12:47:19 | What Investors Should Know About Amicus Therapeutics, Inc.'s NASDAQ:FOLD Financial Strength

2019-04-05 12:27:49 | Janney: Amicus Therapeutics Has Significant Upside From Gene Therapy Pipeline

2019-03-30 09:30:01 | Amicus Therapeutics FOLD Up 12.4% Since Last Earnings Report: Can It Continue?

2019-03-29 07:10:00 | Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon — What Drives Growth in Today's Competitive Landscape

2019-03-20 07:00:00 | Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200

2019-03-07 14:52:00 | Amicus Therapeutics Looks Impressive If it Can Rally Above $18

2019-03-06 14:39:58 | Will Amicus Therapeutics, Inc.’s NASDAQ:FOLD Earnings Grow In The Years Ahead?

2019-03-01 11:59:04 | Amicus FOLD Reports Wider-than-Expected-Loss for 2018

2019-02-28 14:39:52 | Edited Transcript of FOLD earnings conference call or presentation 28-Feb-19 1:30pm GMT

2019-02-28 12:04:47 | Amicus Therapeutics Inc FOLD Q4 2018 Earnings Conference Call Transcript

2019-02-28 07:00:00 | Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates

2019-02-28 06:30:00 | Amicus Therapeutics, Inc. to Host Earnings Call

2019-02-26 07:32:04 | N.J. biotech firm expanding to Philadelphia, creating 200 new jobs